The HemOnc Pulse Live at ASH 2022: Elias Jabbour, MD, on Immunotherapy Advances in ALL

By Chadi Nabhan, MD, MBA, FACP, Elias Jabbour, MD - Last Updated: December 13, 2022

Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about advances in frontline treatment for acute lymphoblastic leukemia (ALL), immunotherapy, using minimal residual disease data to tailor therapy, strategies for treating patients with relapsed disease, and more, during the 2022 American Society of Hematology Annual Meeting.

 

Post Tags:ASH22
Advertisement
Advertisement
Advertisement
Editorial Board